Nucleus Network Begins Recruitment for Phase 2 Trial of Promising Novavax NVX-CoV2373 COVID-19 VaccinePosted by On

Dr Jason Lickliter Nucleus Network Chief Medical Officer speaking with a participant.

Nucleus Network staff authenticating the dosing.

Clinical trial participants.

Nucleus Network, has commenced recruitment of volunteers for the Phase 2 trial of Novavax’ COVID-19 vaccine, at its Melbourne and Brisbane clinics in Australia.

We’ve had an unprecedented level of interest in a clinical trial for a COVID vaccine, and we hope for this to continue, so we can provide the most reliable data on the effects and safety.”

— Dr Jason Lickliter, Chief Medical Officer at Nucleus Network

MELBOURNE, VICTORIA, AUSTRALIA, August 28, 2020 / — Australia’s largest Phase 1 Clinical trials specialist, Nucleus Network, has today commenced recruitment of volunteers for the Phase 2 trial of NVX CoV2373, a SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, at its Melbourne and Brisbane clinics.

“Following on from a positive Phase 1 trial that started back in May, Nucleus Network has begun the process of recruiting participants for the Phase 2 COVID-19 vaccine trial in Australia on behalf of Novavax, Inc.,” Says Nucleus Network Principal Investigator Dr Paul Griffin. “Novavax is the developer of NVX-CoV2373 and sponsor of the trial, with funding support from the Norway-based Coalition for Epidemic Preparedness Innovations (CEPI), joining the global response to this pandemic.

Dosing will commence in Melbourne on the 2nd of September. The study will comprise of approximately 155 people will be part of this randomised, placebo-controlled, observer-blinded study, with 125 at the Melbourne clinic, and a further 30 at Nucleus Network’s Brisbane facility.

Clinical trials will continue at Nucleus Network’s Melbourne facility during the Stage 4 lockdown, with Nucleus Network able to continue operations as part of the Professional, Scientific and Technical services sector. With the Melbourne clinic classified as a permitted workplace, participants will be allowed to travel beyond 5km from their home to participate as a volunteer.

Participants will initially be screened via phone call, before attending a screening session on the day of dosing. Additional safeguards include temperature screening on arrival, nasal swab tests for all participants, frequent sanitising and cleaning for all staff and participants, increased bed spacing, wearing of Personal Protective Equipment (PPE) by medical officers, nursing staff and other clinical staff during all participant interactions, and infection prevention and control procedures in line with the Victorian Department of Health and Human Services.

“We appreciate the interest from the general public, and the willingness…

Original Author Link click here to read complete story..



Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.